Literature DB >> 27349614

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy.

Thomas Powles1, Michael Staehler2, Börje Ljungberg3, Karim Bensalah4, Steven E Canfield5, Saeed Dabestani6, Rachel H Giles7, Fabian Hofmann8, Milan Hora9, Markus A Kuczyk10, Thomas Lam11, Lorenzo Marconi12, Axel S Merseburger13, Alessandro Volpe14, Axel Bex15.   

Abstract

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cabozantinib; European Association of Urology; Guidelines; Nivolumab; Renal cancer

Mesh：

Substances：

Year:  2016        PMID： 27349614     DOI： 10.1016/j.eururo.2016.06.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  21 in total

1.  Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.

Authors:  C Rothermundt; J von Rappard; T Eisen; B Escudier; V Grünwald; J Larkin; D McDermott; J Oldenburg; C Porta; B Rini; M Schmidinger; C N Sternberg; P M Putora
Journal:  World J Urol       Date:  2016-08-03       Impact factor: 4.226

2.  Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort.

Authors:  Viktor Grünwald; Marion Dietrich; Gregory R Pond
Journal:  World J Urol       Date:  2018-04-13       Impact factor: 4.226

Review 3.  [TKI 2.0 - changes in the medical treatment of renal cell carcinoma].

Authors:  V Stühler; S Kruck; M Hegemann; M Notohamiprodjo; T Todenhöfer; N Kröger; A Stenzl; J Bedke
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

Review 4.  Cabozantinib: A Review in Advanced Renal Cell Carcinoma.

Authors:  Zaina T Al-Salama; Gillian M Keating
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

5.  Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.

Authors:  Jie Ding; Chiuan-Ren Yeh; Yin Sun; Changyi Lin; Joshua Chou; Zhenyu Ou; Chawnshang Chang; Jun Qi; Shuyuan Yeh
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

Review 6.  Biomarkers of Renal Tumors: the Current State and Clinical Perspectives.

Authors:  Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin
Journal:  Curr Urol Rep       Date:  2017-01       Impact factor: 3.092

7.  Identifying the role of transient receptor potential channels (TRPs) in kidney renal clear cell carcinoma and their potential therapeutic significances using genomic and transcriptome analyses.

Authors:  Jie Ren; Qihang Yuan; Jifeng Liu; Lei Zhong; Hanshuo Li; Guangzhen Wu; Feng Chen; Qizhen Tang
Journal:  BMC Med Genomics       Date:  2022-07-13       Impact factor: 3.622

8.  NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation.

Authors:  Jiatian Lin; Xiangling Chen; Hongjian Yu; Shasha Min; Yequn Chen; Zesong Li; Xina Xie
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

9.  IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors.

Authors:  Hailong Ruan; Zhengshuai Song; Qi Cao; Dong Ni; Tianbo Xu; Keshan Wang; Lin Bao; Junwei Tong; Haibing Xiao; Wen Xiao; Gong Cheng; Zhiyong Xiong; Huageng Liang; Di Liu; Liang Wang; Tredan Olivier; Boyle Helen Jane; Hongmei Yang; Xiaoping Zhang; Ke Chen
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

10.  Extracellular miR-224 as a prognostic marker for clear cell renal cell carcinoma.

Authors:  Nakanori Fujii; Hiroshi Hirata; Koji Ueno; Junichi Mori; Shintaro Oka; Kosuke Shimizu; Yoshihisa Kawai; Ryo Inoue; Yoshiaki Yamamoto; Hiroaki Matsumoto; Tomoyuki Shimabukuro; Koichi Udoh; Yoshinobu Hoshii; Rajvir Dahiya; Hideyasu Matsuyama
Journal:  Oncotarget       Date:  2017-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.